Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

Haematologica

Volumn 98, Issue 10, 2013, Pages

  Racil, Zdenek ^a,b   Razga, Filip ^a   Drapalova, Jana ^c   Buresova, Lucie ^b   Zackova, Daniela ^a   Palackova, Martina ^a   Semerad, Lukas ^a   Malaskova, Ludmila ^a   Haluzik, Martin ^c   Mayer, Jiri ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Glucose metabolism; Nilotinib; Tyrosin kinase inhibitor

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; INSULIN; NILOTINIB;

ADULT; AGED; B LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DYSLIPIDEMIA; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; ORAL GLUCOSE TOLERANCE TEST;

GLUCOSE METABOLISM; NILOTINIB; TYROSIN KINASE INHIBITOR;

ADULT; AGED; BLOOD GLUCOSE; FEMALE; GLUCOSE; HUMANS; INSULIN RESISTANCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84884924571     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.086355     Document Type: Letter

References (15)

1. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-9.
2. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21(12):2191-2.
3. Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, et al. Validation of the insulin sensitivity index (ISI(0,120): comparison with other measures. Diabetes Res Clin Pract. 2000;47(3):177-84.
4. Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes. 2010;1(2):36-47.
5. Phillips LK, Prins JB. Update on incretin hormones. Ann NY Acad Sci. 2011;1243:E55-74.
6. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endoc Relat Cancer. 2009;16(4):1103-23.
7. Frasca F, Pandini G, Malaguarnera R, Mandarino A, Messina RL, Sciacca L, et al. Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. J Biol Chem. 2007;282 (36):26077-88.
8. Genua M, Pandini G, Cassarino MF, Messina RL, Frasca F. c-Abl and insulin receptor signalling. Vitam Horm. 2009;80:77-105.
9. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007;115(12):1537-43.
10. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens). 2012;11(1):8-20.
11. Mohlig M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF, et al. Insulin decreases human adiponectin plasma levels. Horm Metab Res. 2002;34(11-12):655-8.
12. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270-87.
13. Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009;119(2):315-22.
14. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23(1):85-9.
15. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533-9.